SCHEMBL1474142

SCHEMBL1474142

CCOC(=O)C1CC1(C)c1ccc(SC(F)(F)F)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 2/20 0.35
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
RORC P51449 3/20 0.34
NR1I2 O75469 1/20 0.34
PTPRZ1 P23471 1/20 0.34
MAPT P10636 1/20 0.34
HIF1A Q16665 1/20 0.34
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33
APH1B Q8WW43 1/20 0.33
NCSTN Q92542 1/20 0.33
APH1A Q96BI3 1/20 0.33
PSENEN Q9NZ42 1/20 0.33
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1474477 0.83 ALDH1A1 (0.46) RORCNR1I2MAPTSMN1; SMN2ALDH1A1
SCHEMBL1473952 0.81 ALDH1A1 (0.38) PDE2ASLC6A2SLC6A4SLC6A3PTPRZ1
SCHEMBL23020811 0.81 OPRM1 (0.43) MAPTL3MBTL1PSEN1PSEN2APH1B
SCHEMBL1473939 0.81 POLB (0.47) SLC6A4SLC6A3SMN1; SMN2ALDH1A1EPHX2
SCHEMBL1474012 0.80 RORC (0.41) RORCNR1I2MAPTHIF1APSEN1
SCHEMBL9820733 0.79 MEN1 (0.45) RORCNR1I2MAPTNPC1RAB9A
SCHEMBL1475802 0.79 TSHR (0.39) RORCPTPRZ1MAPTRAB9AL3MBTL1
SCHEMBL15200618 0.79 OPRM1 (0.45) MAPTSMN1; SMN2ALDH1A1
SCHEMBL15977383 0.78 L3MBTL1 (0.49) SLC6A4RORCNR1I2MAPTSMN1; SMN2
SCHEMBL15978556 0.78 L3MBTL1 (0.49) SLC6A4RORCNR1I2MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1861359-B1 N-(N-SULFONYLAMINOMETHYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN PFIZER (US) 2012-11-14 EP disclosed
US-7915448-B2 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists PFIZER INC. (US) 2011-03-29 US disclosed
US-20100035880-A1 SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS PFIZER INC 2010-02-11 US disclosed
US-7622589-B2 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists PFIZER INC. (US) 2009-11-24 US disclosed
US-20060211741-A1 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists PFIZER, INC. 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211741-A1 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists CNR1, HVCN1, CNR2 PDE2A 3868/4885SLC6A2 679/4885SLC6A4 763/4885
US-20100035880-A1 SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS CNR1, HVCN1, CNR2 PDE2A 3858/4885SLC6A2 674/4885SLC6A4 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.